Metformin Actavis

Metformin, the active ingredient in Metformin Actavis, is a biguanide presented as an oral tablet for oral administration. It is used to lower elevated blood glucose levels in adults with type 2 diabetes mellitus, helping to improve glycaemic control as part of a comprehensive diabetes management plan.

GNH USA supplies Metformin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for this essential antidiabetic medication and ensuring consistent quality across markets.

Metformin is an oral antidiabetic agent indicated for the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control by reducing hepatic glucose output and enhancing peripheral insulin sensitivity. - Prediabetes: may delay progression to overt diabetes when combined with lifestyle modification. - Polycystic ovary syndrome (PCOS): helps improve insulin resistance and may restore regular ovulation.

Metformin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, especially during treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Vitamin B12 deficiency: may develop with long‑term use. - Hypoglycaemia: uncommon when used alone but possible with other glucose‑lowering agents. - Acute pancreatitis: very rare inflammatory condition of the pancreas.

Metformin should be used with careful clinical assessment and monitoring.

- Renal function: assess eGFR before initiating and periodically monitor kidney function. - Hepatic disease: use with caution in patients with liver impairment. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia such as severe heart failure or recent myocardial infarction. - Pregnancy and lactation: evaluate risk–benefit; generally avoided unless clearly indicated. - Drug interactions: review concomitant medications for potential pharmacokinetic or pharmacodynamic interactions. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Metformin may interact with several medicines, requiring vigilance.

Major Interactions (Avoid): - Iodinated contrast agents: discontinue metformin before and after imaging to prevent renal impairment. - Cimetidine: can increase metformin plasma concentrations. - Alcohol abuse: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycaemia. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - NSAIDs: may reduce renal perfusion, increasing metformin exposure.